Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 08:00 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

GAL-101 well tolerated; excellent safety and pharmacokinetic profile strongly supports oral administrationNext arms of study, including multiple ascending dose (MAD), underway and expected to complete...
December 23, 2024 11:30 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD

Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular degenerationTrial planned to enroll 110 patients in the US,...
March 08, 2024 04:00 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

GAL-201 specifically targets and binds to misfolded Aβ monomers, preventing their aggregation to toxic Aβ oligomers and protofibrilsAs a consequence, consistent beneficial effects have been...
March 29, 2023 08:00 ET | Source: Galimedix Therapeutics, Inc.

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need

Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open Innovation into Galimedix supports further...
October 29, 2019 08:00 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab

KENSINGTON, Md., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the retina and the brain,...
October 21, 2019 09:45 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit

KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
October 21, 2019 08:30 ET | Source: Galimedix Therapeutics, Inc.

Galimedix Therapeutics, Inc. Appoints Recognized Industry Veteran, Alexander Gebauer, M.D., Ph.D., as Executive Chairman

KENSINGTON, Md. and SHORASHIM, Israel, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., an emerging leader in the development of new solutions for neurodegenerative diseases of the...
October 08, 2019 09:35 ET | Source: Galimedix

Galimedix Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During the American Academy of Ophthalmology Meeting

KENSINGTON, Md. and SHORASHIM, Israel , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, Inc., which is developing new solutions for neurodegenerative diseases of the retina and the brain,...
May 08, 2019 08:00 ET | Source: Galimedix

Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models

KENSINGTON, Md. and SHORASHIM, Israel, May 08, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today presented data...
May 06, 2019 07:00 ET | Source: Galimedix

Galimedix, Inc. Appoints Renowned Industry Veteran and Innovator in the Field of Ophthalmology Thomas Hohman, Ph.D. to Board of Directors

KENSINGTON, Md. and SHORASHIM, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announces the...

Next Page keyboard_arrow_right